Figure 4. Treatment with JQ1 inhibits ES tumor growth in vivo.

Evaluation of the therapeutic potential of JQ1 application. Immune deficient Rag2^−/−γc^−/− mice were injected s.c. with 2×10⁶ ES cells. 5-7 days later these mice received different doses of JQ1 or vehicle i.p., respectively. Delay or inhibition of tumor growth was evaluated. A. Mice were either injected with A673 or SK-N-MC cells and 7 days later received 50 mg/kg JQ1 or vehicle every other day. Mice with an average tumor size >10 mm in diameter were considered as positive and killed. Kaplan–Meier plots of individual experiments with 5 mice per group are shown. B. Mice were injected with tumor cells s.c. and 5 days later received twice daily doses for 14 to 23 days for TC-71 and SK-N-MC, respectively. Top, survival of TC-71 inoculated mice. Bottom, tumor growth after inoculation with SK-N-MC cells. (6 mice/group). C. To analyze intratumoral changes after high dose JQ1 application tumors were collected upon tumor burden (TC-71) or after 23 days (SK-N-MC). The pictures show clear increased expression of cleaved caspase 3 in tumors treated with JQ1. Bar indicates 0.1 mm. D. Variation of tumor growth characteristics analyzed as a function of time until tumors reached >1 cm³ size for TC-71 inoculated mice. E. Determined tumor weight of SK-N-MC inoculated mice at the end of the experiment. **P-value < 0.005, ***P-value < 0.0005.